Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist used to prevent thrombotic events in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
## Primary Indications
* Prevention of thrombotic events in patients with ACS (unstable angina, non-ST-elevation MI, or ST-elevation MI).
* Prevention of thrombotic events in patients with a history of MI (older than 1 year) who are at high risk for occlusive cardiovascular events.
## Adult Dosing
* **ACS:** Loading dose of 180 mg orally once, followed by 90 mg orally twice daily.
* **History of MI (older than 1 year):** 60 mg orally twice daily.
* Duration of therapy typically 12 months for ACS, or longer if clinically indicated and bleeding risk is low. For patients with a history of MI, therapy may be continued long-term if benefit outweighs risk.
## Pediatric Dosing
Dosing has not been established in pediatric patients.
## Dose Adjustments
No dose adjustments are needed based on renal or hepatic impairment, though caution is advised in severe hepatic impairment.
## Contraindications
* Active bleeding.
* History of intracerebral hemorrhage.
* Known hypersensitivity to ticagrelor or any of its components.
## Adverse Effects
* **Common:** Dyspnea, bleeding (including fatal and life-threatening), contusion, epistaxis, hematuria, gastrointestinal hemorrhage.
* **Serious:** Major bleeding, ventricular pauses, bradycardia.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Coadministration with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure. Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure.
* **Aspirin:** Concurrent use with aspirin increases the risk of bleeding. However, it is generally recommended in combination with aspirin for ACS and post-MI indications.
* **Other Antithrombotics:** Concurrent use with other antithrombotics (e.g., other P2Y12 inhibitors, anticoagulants) increases the risk of bleeding.
* **Statins:** Use of ticagrelor with moderate to high-intensity statins may increase statin exposure.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Assess for dyspnea.
* Monitor heart rate and rhythm, especially in patients with risk factors for bradycardia.
* Consider baseline and periodic assessment of hepatic function in patients with severe hepatic impairment.
## Clinical Pearls
* Ticagrelor is generally preferred over clopidogrel in ACS due to faster onset, greater potency, and less inter-individual variability.
* The 180 mg loading dose for ACS is crucial for rapid platelet inhibition.
* Dyspnea is a common side effect and is not typically indicative of a cardiopulmonary process. If severe or persistent, consider alternative agents.
* Discontinuation of ticagrelor before completing the recommended duration of therapy should be carefully considered due to increased risk of thrombotic events.
***
**Disclaimer:** This information is intended for clinical pharmacists and should not be a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.
